Other patient outcomes and characteristics including overall survival status, overall time to recurrence event, tumor grade, number and size of metastatic lymph nodes, expression of ER/PR/HER2, tumor subtypes or tumor PDGFRα mRNA expression were not significantly different when assessing patients based on the presence or absence of HCMV gB DNA in breast tumors or based on HCMV serostatus (Table 3, Table 4 and Table 5). This evidence concerns the gene ESR1 and breast neoplasm.